Last reviewed · How we verify
rhBNP
rhBNP (recombinant human B-type natriuretic peptide) mimics the body's natural natriuretic peptide to promote vasodilation, reduce cardiac preload and afterload, and improve hemodynamics in acute decompensated heart failure.
rhBNP (recombinant human B-type natriuretic peptide) mimics the body's natural natriuretic peptide to promote vasodilation, reduce cardiac preload and afterload, and improve hemodynamics in acute decompensated heart failure. Used for Acute decompensated heart failure.
At a glance
| Generic name | rhBNP |
|---|---|
| Also known as | Recombinant Human Brain Natriuretic Peptide |
| Sponsor | LI ZHAO |
| Drug class | Natriuretic peptide |
| Target | Natriuretic peptide receptor-A (NPR-A) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
BNP is a cardiac hormone normally released by the ventricles in response to stretch and increased pressure. rhBNP binds to natriuretic peptide receptors on vascular smooth muscle and other tissues, activating guanylate cyclase and increasing cGMP levels. This leads to vasodilation, reduced sodium reabsorption in the kidneys, decreased sympathetic tone, and improved cardiac output, making it useful in acute heart failure management.
Approved indications
- Acute decompensated heart failure
Common side effects
- Hypotension
- Headache
- Dizziness
- Renal dysfunction
Key clinical trials
- Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery (NA)
- rhBNP in Type 3 Pulmonary Hypertension (PHASE4)
- Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI (PHASE4)
- Effect of rhBNP on CMD in Patients With STEMI After PPCI (NA)
- Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure (NA)
- Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot (NA)
- Early rhBNP on Myocardial Work in Patients With STEMI (PHASE4)
- Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhBNP CI brief — competitive landscape report
- rhBNP updates RSS · CI watch RSS
- LI ZHAO portfolio CI